The Indian Patent Act have provisions for making available cheap and affordable medicines.
Department of Industrial Policy and Promotion has informed that so far one Compulsory license has been granted by the Controller General of Patents, Designs and Trade Marks to a drug manufacturing company since the amendment of the Patents Act in 2005 for an application filed under Section 84 of the Patents Act (as amended in 2005). As per the orders of the Controller of Patents, Mumbai compulsory license has been granted to M/s Natco for manufacture of “NEXAVAR”, M/s Natco Pharma Ltd. are required to sell this drug at a price not exceeding Rs. 8880/- for a pact of 120 tablets, required for a month’s treatment which was earlier being sold by M/s Bayer Corporation at Rs. 2,80,428/- for one month treatment.
This information was given by the Minister of State for Chemicals and Fertilisers, Shri Srikant Kumar Jena in a written reply in the Lok Sabha today.
Department of Industrial Policy and Promotion has informed that so far one Compulsory license has been granted by the Controller General of Patents, Designs and Trade Marks to a drug manufacturing company since the amendment of the Patents Act in 2005 for an application filed under Section 84 of the Patents Act (as amended in 2005). As per the orders of the Controller of Patents, Mumbai compulsory license has been granted to M/s Natco for manufacture of “NEXAVAR”, M/s Natco Pharma Ltd. are required to sell this drug at a price not exceeding Rs. 8880/- for a pact of 120 tablets, required for a month’s treatment which was earlier being sold by M/s Bayer Corporation at Rs. 2,80,428/- for one month treatment.
This information was given by the Minister of State for Chemicals and Fertilisers, Shri Srikant Kumar Jena in a written reply in the Lok Sabha today.
